UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

The Journal of cell biology, 2009-12, Vol.187 (6), p.859-874

2009

Volltextzugriff (PDF)

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Frontiers in oncology, 2024-08, Vol.14

2024

Volltextzugriff (PDF)

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover

American Journal of Physiology: Cell Physiology, 2007-08, Vol.293 (2), p.C712-C722

2007

Volltextzugriff (PDF)

Microtubule-independent secretion requires functional maturation of Golgi elements

Journal of cell science, 2016-09, Vol.129 (17), p.3238-3250

2016

Volltextzugriff (PDF)

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.421-421

2020

Volltextzugriff (PDF)

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo

Anti-cancer drugs, 2023-04, Vol.34 (4), p.532

2023

Volltextzugriff (PDF)

Stimulatory role of dopamine on fibroblast growth factor‐2 expression in rat striatum

Journal of neurochemistry, 2001-02, Vol.76 (4), p.990-997

2001

Volltextzugriff (PDF)

Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions

Biological psychiatry (1969), 2004-04, Vol.55 (7), p.708-714

2004

Volltextzugriff (PDF)

Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.LB-C12-LB-C12

2019

Volltextzugriff (PDF)

Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity

Brain Research Reviews, 2001-11, Vol.37 (1), p.249-258

2001

Volltextzugriff (PDF)

Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5646-5646

2022

Volltextzugriff (PDF)

Differential interaction of the Pafah1b alpha subunits with the Reelin transducer Dab1

Brain research, 2009-04, Vol.1267, p.1-8

2009

Volltextzugriff (PDF)

Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity

Journal of neuroscience research, 2003-06, Vol.72 (5), p.622-628

2003

Volltextzugriff (PDF)

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

The Journal of experimental medicine, 2009-12, Vol.206 (13), p.i33-i33

2009

Volltextzugriff (PDF)

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover

American Journal of Physiology: Cell Physiology, 2007, Vol.62 (2)

2007

Volltextzugriff (PDF)

Calcium-dependent modulation of FGF-2 expression in cultured cerebellar granule neurons

Neuroreport, 2000-11, Vol.11 (16), p.3615-3619

2000

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)
Japanisch
(5)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover

Microtubule-independent secretion requires functional maturation of Golgi elements

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo

Stimulatory role of dopamine on fibroblast growth factor‐2 expression in rat striatum

Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions

Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer

Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity

Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division

Differential interaction of the Pafah1b alpha subunits with the Reelin transducer Dab1

Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover

Calcium-dependent modulation of FGF-2 expression in cultured cerebellar granule neurons

Suchergebnisse filtern